Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE Reports Fourth Quarter and Fiscal Year 2005 Operational and Financial Results
OXiGENE Reports Fourth Quarter and Fiscal Year 2005 Operational and Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--March 1, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): Company Achieves Regulatory and Clinical Milestones, Strengthens Balance Sheet, Identifies an Additional Mechanism of
View HTML
Toggle Summary Oxigene Schedules Q4 and Year-End FY05 Conference Call; Live Internet Webcast to be Available at www.oxigene.com
Oxigene Schedules Q4 and Year-End FY05 Conference Call; Live Internet Webcast to be Available at www.oxigene.com WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 14, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic
View HTML
Toggle Summary OXiGENE to Present at the BIO CEO & Investor Conference; Company Presentation to Be Available via Webcast
OXiGENE to Present at the BIO CEO & Investor Conference; Company Presentation to Be Available via Webcast WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 13, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases,
View HTML
Toggle Summary OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC)
OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC) WALTHAM, Mass., Feb 03, 2006 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) -- Combretastatin A4P (CA4P) will be Evaluated with
View HTML
Toggle Summary OXiGENE Announces Completion of Public Offering of Common Stock
OXiGENE Announces Completion of Public Offering of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 21, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced that it completed a
View HTML
Toggle Summary OXiGENE Announces Pricing of Public Offering
OXiGENE Announces Pricing of Public Offering WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 15, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced the pricing of its public offering of
View HTML
Toggle Summary OXiGENE Receives Regulatory Clearance to Commence Phase III Clinical Trial for Advanced, Inoperable Non-Small Cell Lung Cancer (NSCLC)
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 12, 2005--OXiGENE, Inc.     Phase III Study to Evaluate CA4P in Combination with Radiotherapy and Chemotherapy; Trial Endpoint Targets an Increase in Median Survival Benefit First Vascular Disrupting Agent to Enter a Phase III Clinical Trial   OXiGENE, Inc.
View HTML
Toggle Summary OXiGENE to Commence First Ever Oncology Clinical Trial Combining a Vascular Disrupting Compound, Combretastatin A4P, with an Anti-Angiogenic Agent, Avastin
OXiGENE to Commence First Ever Oncology Clinical Trial Combining a Vascular Disrupting Compound, Combretastatin A4P, with an Anti-Angiogenic Agent, Avastin - Dose-Escalating Study Will Commence to Assess the Safety, Tolerability and Anti-Tumor Effects of a Promising New Potential Treatment for
View HTML
Toggle Summary David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors
David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors WALTHAM, Mass., Dec 01, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): -- Dr.
View HTML
Toggle Summary OXiGENE Announces Proposed Offering of Six Million Shares of Common Stock
OXiGENE Announces Proposed Offering of Six Million Shares of Common Stock WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 1, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, today announced that it has
View HTML